Mining Pharma’s Reshoring Rush

The COVID-19 pandemic spurred a renewed focus on reshoring pharmaceutical manufacturing to the U.S., leading to significant government investments in domestic production. While these efforts have increased capacity and created excitement, experts caution that long-term sustainability requires strategic planning and continued support to help ensure lasting benefits for the U.S. supply chain. Part 1: Mining the reshoring rush: Targeting government spending > Part 2: Mining the reshoring rush: Sustaining efforts once infrastructure investments dry up >